Impact of abiraterone on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives

References

• ChiKNBjartellADearnaleyDCastration-resistant prostate cancer: from new pathophysiology to new treatment targetsEur Urol200956459460519560857
   PubMed Web of Science ®Google Scholar
• HellerstedtBAPientaKJThe current state of hormonal therapy for prostate cancerCA Cancer J Clin200252315417912018929
   PubMed Web of Science ®Google Scholar
• SharifiNGulleyJLDahutWLAndrogen deprivation therapy for prostate cancerJAMA2005294223824416014598
   PubMed Web of Science ®Google Scholar
• BubleyGJCarducciMDahutWEligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working GroupJ Clin Oncol199917113461346710550143
   PubMed Web of Science ®Google Scholar
• ScherHIHalabiSTannockIProstate Cancer Clinical Trials Working GroupDesign and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working GroupJ Clin Oncol20082671148115918309951
   PubMed Web of Science ®Google Scholar
• CostaLBadiaXChowELiptonAWardleyAImpact of skeletal complications on patients’ quality of life, mobility, and functional independenceSupport Care Cancer200816887988918392862
   PubMed Web of Science ®Google Scholar
• PensonDFLitwinMSThe physical burden of prostate cancerUrol Clin North Am200330230531312735506
   PubMed Web of Science ®Google Scholar
• SullivanPWMulaniPMFishmanMSleepDQuality of life findings from a multicenter, multinational, observational study of patients with metastatic hormone-refractory prostate cancerQual Life Res200716457157517294287
   PubMed Web of Science ®Google Scholar
• PetrylakDPTangenCMHussainMHDocetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancerN Engl J Med2004351151513152015470214
   PubMed Web of Science ®Google Scholar
• TannockIFde WitRBerryWRDocetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancerN Engl J Med2004351151502151215470213
   PubMed Web of Science ®Google Scholar
• BertholdDRPondGRSobanFde WitREisenbergerMTannockIFDocetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 studyJ Clin Oncol20082624224518182665
   PubMed Web of Science ®Google Scholar
• SealBSAscheCVPutoKAllenPDEfficacy, patient-reported outcomes (PROs), and tolerability of the changing therapeutic landscape in patients with metastatic prostate cancer (MPC): a systematic literature reviewValue Health201316587289023947983
   PubMed Web of Science ®Google Scholar
• NussbaumNGeorgeDJAbernethyAPPatient experience in the treatment of metastatic castration-resistant prostate cancer: state of the scienceProstate Cancer Prostatic Dis20161911112126832363
   PubMed Web of Science ®Google Scholar
• VasaitisTSBrunoRDNjarVCCYP17 inhibitors for prostate cancer therapyJ Steroid Biochem Mol Biol2011125233121092758
   PubMed Web of Science ®Google Scholar
• YapTACardenCPAttardGde BonoJSTargeting CYP17: established and novel approaches in prostate cancerCurr Opin Pharmacol20088444945718619560
   PubMed Web of Science ®Google Scholar
• YangLPAbiraterone acetate: in metastatic castration-resistant prostate cancerDrugs201171152067207721985170
   PubMed Web of Science ®Google Scholar
• HoySMAbiraterone acetate: a review of its use in patients with metastatic castration-resistant prostate cancerDrugs201373182077209124271422
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human ServicesGuidance for Industry. Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling ClaimsSilver Spring, MDUS FDA2006
   Google Scholar
• CalvertMBlazebyJAltmanDGReporting of patient-reported outcomes in randomized trials: the CONSORT PRO extensionJAMA201330981482223443445
   PubMed Web of Science ®Google Scholar
• ClarkMJHarrisNGriebschIKaschinskiDCopley-MerrimanCPatient-reported outcome labeling claims and measurement approach for metastatic castration-resistant prostate cancer treatments in the United States and European UnionHealth Qual Life Outcomes20141210424989428
   PubMed Web of Science ®Google Scholar
• CellaDFTulskyDSGrayGThe Functional Assessment of Cancer Therapy scale: development and validation of the general measureJ Clin Oncol19931135705798445433
   PubMed Web of Science ®Google Scholar
• Winstead-FryPSchultzAPsychometric analysis of the Functional Assessment of Cancer Therapy-General (FACT-G) scale in a rural sampleCancer19977912244624529191537
   PubMed Web of Science ®Google Scholar
• OvercashJExtermannMParrJPerryJBalducciLValidity and reliability of the FACT-G scale for use in the older person with cancerAm J Clin Oncol200124659159611801761
   PubMed Web of Science ®Google Scholar
• WebsterKCellaDYostKThe functional assessment of chronic illness therapy (FACIT) measurement system: properties, applications, and interpretationHealth Qual Life Outcomes200317914678568
   PubMedGoogle Scholar
• EsperPMoFChodakGSinnerMCellaDPientaKJMeasuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrumentUrology19975069209289426724
   PubMed Web of Science ®Google Scholar
• de BonoJSLogothetisCJMolinaACOU-AA-301 InvestigatorsAbiraterone and increased survival in metastatic prostate cancerN Engl J Med2011364211995200521612468
   PubMed Web of Science ®Google Scholar
• FizaziKScherHIMolinaACOU-AA-301 InvestigatorsAbiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 studyLancet Oncol2012131098399222995653
   PubMed Web of Science ®Google Scholar
• LogothetisCJBaschEMolinaAEffect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trialLancet Oncol201213121210121723142059
   PubMed Web of Science ®Google Scholar
• HarlandSStaffurthJMolinaACOU-AA-301 InvestigatorsEffect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapyEur J Cancer201349173648365723973186
   PubMed Web of Science ®Google Scholar
• SternbergCNMolinaANorthSEffect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapyAnn Oncol20132441017102523152362
   PubMed Web of Science ®Google Scholar
• RyanCJSmithMRde BonoJSCOU-AA-302 InvestigatorsAbiraterone in metastatic prostate cancer without previous chemotherapyN Engl J Med2013368213814823228172
   PubMed Web of Science ®Google Scholar
• RyanCJSmithMRFizaziKCOU-AA-302 InvestigatorsAbiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 studyLancet Oncol201516215216025601341
   PubMed Web of Science ®Google Scholar
• BaschEAutioKRyanCJAbiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trialLancet Oncol20131412193119923580956
   PubMed Web of Science ®Google Scholar
• RathkopfDESmithMRde BonoJSUpdated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)Eur Urol201466581582524647231
   PubMed Web of Science ®Google Scholar
• SaadFShoreNVan PoppelHImpact of bone-targeted therapies in chemotherapy-naive metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302Eur Urol20156857057725985882
   PubMed Web of Science ®Google Scholar
• BaschEAutioKASmithMREffects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohortEur Urol201567231031824631409
   PubMed Web of Science ®Google Scholar
• CellaDLiSLiTKheohTToddMBBaschERepeated measures analysis of patient-reported outcomes in prostate cancer after abiraterone acetateJ Community Support Oncol201614414815427152513
   PubMedGoogle Scholar
• AzadAAEiglBJLeibowitz-AmitROutcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance statusEur Urol201567344144724508071
   PubMed Web of Science ®Google Scholar
• Van PraetCRotteySVan HendeFAbiraterone acetate post-docetaxel for metastatic castration-resistant prostate cancer in the Belgian compassionate use programUrol Oncol2016346254.e7254.e13
   Web of Science ®Google Scholar
• CaffoODe GiorgiUFratinoLSafety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: results of the Italian Named Patient ProgrammeBJU Int2015115576477124988879
   PubMed Web of Science ®Google Scholar
• SunYZouQSunZAbiraterone acetate for metastatic castration-resistant prostate cancer after docetaxel failure: a randomized, double-blind, placebo-controlled phase 3 bridging studyInt J Urol201623540441126879374
   PubMed Web of Science ®Google Scholar
• KwakCWuTTLeeHMAbiraterone acetate and prednisolone for metastatic castration-resistant prostate cancer failing androgen deprivation and docetaxel-based chemotherapy: a phase II bridging study in Korean and Taiwanese patientsInt J Urol201421121239124425099185
   PubMed Web of Science ®Google Scholar
• ProcopioGGrassiPTestaISafety of abiraterone acetate in castration-resistant prostate cancer patients with concomitant cardiovascular risk factorsAm J Clin Oncol201538547948224064757
   PubMed Web of Science ®Google Scholar
• IacovelliRVerriECossu RoccaMThe incidence and relative risk of cardiovascular toxicity in patients treated with new hormonal agents for castration-resistant prostate cancerEur J Cancer201551141970197726169016
   PubMed Web of Science ®Google Scholar
• PhillipsRProstate cancer: patient-reported outcomes of first-line abiraterone therapyNat Rev Urol201310619
   Google Scholar